Monte Rosa reports positive Phase 1 GFORCE-1 results for MRT-8102 in elevated CVD-risk subjects

By Public Technologies
  • Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102 in obese subjects with elevated cardiovascular risk.
  • Findings were presented now, with a conference call and webcast scheduled for today.
  • Treatment lowered multiple inflammatory and clotting-related disease drivers toward levels seen in healthy volunteers, supporting its proposed cardiovascular rationale.
  • Safety profile looked comparable to placebo over dosing and follow-up, with no serious adverse events reported.
  • Phase 2 studies are planned in coronary artery disease in H1 2027, with additional mid-stage trials in gout and hidradenitis suppurativa.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837501) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.